11 Atopic Dermatitis Clinical Trials in Minneapolis, MN (2026)

Q: How do I join a clinical trial in Minneapolis?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you.

Recruiting Atopic Dermatitis Studies in Minneapolis

NCT06662500Recruiting

FORWARD CAD IDE Study

The FORWARD CAD IDE Study is a Prospective, Multicenter, Single-Arm, Investigational Device Exemption (IDE) Study conducted to assess the safety and effectiveness of the Shockwave Intravascular Lithot...

Minneapolis, MNNA408 participantsShockwave Medical, Inc.

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

Minneapolis, MNPHASE1351 participantsFate Therapeutics

View Study Details

NCT06712823Recruiting

An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894)....

Minneapolis, MNPHASE2200 participantsCrinetics Pharmaceuticals Inc.

View Study Details

NCT06217822Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Researchers are looking for a better way to treat participants who have metastatic castration-resistant prostate cancer (mCRPC). mCRPC is a cancer of the prostate (male reproductive gland found below...

Minneapolis, MNPHASE1198 participantsBayer

View Study Details

NCT06123481Recruiting

Autologous Bone Marrow Aspirate Treatment for Early-Stage Osteonecrosis

Osteonecrosis of the femoral head (ONFH) is a debilitating musculoskeletal disease that is characterized by localized death of bone cells and associated cellular elements within the subchondral bone. ...

Minneapolis, MNNA192 participantsJohns Hopkins University

View Study Details

NCT06190197Recruiting

Prophylactic Antibiotics in Cystectomy With Diversion

Using a randomized 2 arm design, this study is being conducted to test for non-inferiority of no prophylactic antibiotic therapy versus the prophylactic oral antibiotic, nitrofurantoin, through compar...

Minneapolis, MNEARLY_PHASE1120 participantsUniversity of Minnesota

View Study Details

NCT07223697Recruiting

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials....

Minneapolis, MNPHASE2120 participantsHoffmann-La Roche

View Study Details

NCT06801236Recruiting

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC)....

Minneapolis, MNPHASE188 participantsAcerand Therapeutics (Hong Kong) Limited

View Study Details

NCT07591649Recruiting

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting...

Minneapolis, MNPHASE118 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT06693986Recruiting

Adenovirus (RGDCRAdCOX2F)

This is a single center, Phase I dose finding study of a single direct tumor injection of an RGD modified conditionally replicative adenovirus (RGDCRAdcox2F) in persons with adenocarcinoma of the panc...

Minneapolis, MNPHASE118 participantsMasonic Cancer Center, University of Minnesota

View Study Details

NCT06058520Recruiting

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or ...

Minneapolis, MNEARLY_PHASE116 participantsUniversity of Minnesota

View Study Details

About Atopic Dermatitis Clinical Trials in Minneapolis

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 11 atopic dermatitis clinical trials recruiting participants in Minneapolis, MN. These studies are seeking a combined 1,729 participants. Research is being sponsored by Shockwave Medical, Inc., Fate Therapeutics, Crinetics Pharmaceuticals Inc. and 6 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Minneapolis — FAQ

Are there atopic dermatitis clinical trials in Minneapolis?

Yes, there are 11 atopic dermatitis clinical trials currently recruiting in Minneapolis, MN. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Minneapolis?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Minneapolis research site will contact you about next steps.

Are clinical trials in Minneapolis free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Minneapolis studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 11 active trials in Minneapolis are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 15, 2026 from ClinicalTrials.gov